- $844.34m
- $858.45m
- $463.41m
- 73
- 43
- 49
- 55
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 80.2 | 141 | 218 | 381 | 463 |
Cost of Revenue | |||||
Gross Profit | 14.7 | 33.3 | 57.1 | 146 | 178 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 111 | 171 | 277 | 458 | 537 |
Operating Profit | -30.5 | -29.2 | -59 | -77.1 | -73.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -31 | -31.1 | -61.4 | -79 | -67.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -31 | -31.1 | -61.4 | -79 | -67.5 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -31 | -31.1 | -61.4 | -79.1 | -67.5 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -31 | -39.9 | -61.4 | -79.1 | -67.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.683 | -0.893 | -1.19 | -1.63 | -1.26 |
Dividends per Share |